Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 3/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.42 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.42 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26323681 | 0.90 | DYRK1A (0.43) | PRKCIERN1DYRK1ADYRK1BDYRK2 | |
| SCHEMBL27382765 | 0.83 | PNMT (0.47) | PRKCIERN1DYRK1ADYRK1BDYRK2 | |
| SCHEMBL592019 | 0.80 | ADRA2A (0.53) | MAPK1TDP1CYP3A4TRPA1MAPT | |
| SCHEMBL10313452 | 0.80 | PRKCI (0.47) | PRKCIERN1DYRK1ADYRK1BDYRK2 | |
| SCHEMBL29540837 | 0.80 | ADRA2A (0.53) | MAPK1TDP1CYP3A4TRPA1MAPT | |
| SCHEMBL1019756 | 0.77 | ADRA2A (0.46) | ERN1MAPK1TDP1CYP3A4TRPA1 | |
| SCHEMBL21124236 | 0.76 | MAPT (0.49) | MAPK1TDP1MAPTADRA2AADRA2B | |
| SCHEMBL140824 | 0.73 | HTR3E (0.53) | MAPK1TDP1CYP3A4TRPA1MAPT | |
| SCHEMBL29648863 | 0.73 | HTR3E (0.53) | MAPK1TDP1CYP3A4TRPA1MAPT | |
| SCHEMBL3844804 | 0.73 | ACACB (0.48) | PRKCIERN1DYRK1ADYRK1BDYRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119118440-A | Method for efficiently treating butanone oxime production wastewater | 浙江锦华新材料股份有限公司 | 2024-12-13 | — | — | CN | claimed |
| US-20240154124-A1 | NEGATIVE ELECTRODE PLATE AND LITHIUM-ION BATTERY COMPRISING SAME | ZHUHAI COSMX BATTERY CO., LTD. (CN) | 2024-05-09 | — | — | US | claimed |
| CN-115710481-A | Single-component environment-friendly humidity-heat-resistant modified sealant and preparation method thereof | 山东北方现代化学工业有限公司 | 2023-02-24 | — | — | CN | claimed |
| EP-4713378-A1 | ESTERIFIED ETHANOLAMINES FOR PREPARING ISOCYANURATE POLYMERS | Covestro Deutschland AG (DE) | 2026-03-25 | — | — | EP | disclosed |
| CN-119118440-B | Method for efficiently treating butanone oxime production wastewater | 浙江锦华新材料股份有限公司 | 2025-08-05 | — | — | CN | disclosed |
| EP-3774961-B1 | ADDUCTS OF AMINE CATALYSTS FOR PRODUCING ISOCYANURATE POLYMERS | COVESTRO DEUTSCHLAND AG (DE) | 2025-01-15 | — | — | EP | disclosed |
| CN-119118440-A | Method for efficiently treating butanone oxime production wastewater | 浙江锦华新材料股份有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-119118440-A | Method for efficiently treating butanone oxime production wastewater | 浙江锦华新材料股份有限公司 | 2024-12-13 | — | — | CN | disclosed |
| WO-2024236000-A1 | ESTERIFIED ETHANOLAMINES FOR PREPARING ISOCYANURATE POLYMERS | COVESTRO DEUTSCHLAND AG (DE) | 2024-11-21 | — | — | WO | disclosed |
| EP-4464727-A1 | ESTERIFIED ETHANOLAMINES FOR THE PREPARATION OF ISOCYANURATE POLYMERS | Covestro Deutschland AG (DE) | 2024-11-20 | — | — | EP | disclosed |
| CN-114380874-B | Macrolide antibiotics, preparation method and application thereof | 中国医学科学院医药生物技术研究所 | 2024-06-21 | — | — | CN | disclosed |
| WO-2005056554-A2 | AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2005-06-23 | — | — | WO | disclosed |
| WO-2005051381-A1 | Substituted urea-octatydroindols as antagonists of melanin concentrating hormone receptor 1 (MCH1R) | BIOVITRUM AB (SE) | 2005-06-09 | — | — | WO | disclosed |
| US-20050054634-A1 | Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents | AKARNA THERAPEUTICS, LTD. (GB) | 2005-03-10 | — | — | US | disclosed |
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-12-23 | — | — | US | disclosed |
| WO-2004100946-A1 | 1- (2H-PYRAZOL -3-YL) -3YL) {4-`1- (BENZOYL) -PIPERIDIN-4-YLMETHYL!-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF IMFLAMMATIONS | AVENTIS PHARMACEUTICALS INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| EP-1437344-A1 | BENZENE DERIVATIVES,PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
| US-6159979-A | Bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5HT1A, 5HT1B and 5HT1D receptor antagonistic activity | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-12-12 | — | — | US | disclosed |
| EP-0975614-A1 | A BICYCLIC ARYL OR A BICYCLIC HETEROCYCLIC RING CONTAINING COMPOUNDS HAVING A COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ANTAGONISTIC ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998047885-A1 | A BICYCLIC ARYL OR A BICYCLIC HETEROCYCLIC RING CONTAINING COMPOUNDS HAVING A COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ANTAGONISTIC ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054634-A1 | Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents | GPR119, IRS1, INSR | PRKCI 3498/4885ERN1 2099/4885DYRK1A 3109/4885 |
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | HRH4, HRH2, HRH1 | PRKCI 4830/4885ERN1 3374/4885DYRK1A 3852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.